sars cov 2 target sequence Search Results


synthetic rna containing target sequence sars-cov-2 isolate wa1 sequence  (Bio-Synthesis Inc)
90
Bio-Synthesis Inc synthetic rna containing target sequence sars-cov-2 isolate wa1 sequence
(A) Schematic of <t>SARS-CoV-2</t> vaccine evaluation and challenge in rhesus macaques. Orange circles represent ChAd immunization (5×10 11 VP), blue squares represent SAM vaccination at varying doses and black circle represents challenge with SARS-CoV-2 virus. N = 5/group. (B) spike S1 IgG endpoint titers, geometric mean (annotated) and geometric SD. LOD = 50, samples below LOD set to ½ LOD. (C) IFNγ ELISpot (SFU/10 6 PBMCs) at specified timepoint post immunization, following overnight stimulation with overlapping peptide pool spanning spike antigen. Mean (annotated) +/-SEM. (D) IL-4 vs IFNγ ELISpot of PBMCs assessed 1-week post boost immunization. Individual animal values (n=5/group). Background corrected values. Diagonal line represents unity line. (E) Pseudovirus neutralization titers (50% inhibition, NT50) assessed in sera at specified timepoint post immunization. LOD = 50, samples < LOD set to ½ LOD. Geometric mean (annotated) and SD. HCS = human convalescent serum assessed by same assay. C = PBS control injected animals assessed 8 weeks post injection. (F) Live virus micro-neutralizing titer (50% inhibition, NT50) at specified timepoint post immunization and post SARS-CoV-2 challenge, geometric mean (annotated) and geometric SD. LOD = 20, samples below LOD set to ½ LOD.
Synthetic Rna Containing Target Sequence Sars Cov 2 Isolate Wa1 Sequence, supplied by Bio-Synthesis Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sars+cov+2+target+sequence/synthetic+rna+containing+corresponding+target+sequence+sars+cov+2+isolate+wa1+sequence/bio_rxiv__2021__11__08__467773-265-12-21
Average 90 stars, based on 1 article reviews
synthetic rna containing target sequence sars-cov-2 isolate wa1 sequence - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) Schematic of SARS-CoV-2 vaccine evaluation and challenge in rhesus macaques. Orange circles represent ChAd immunization (5×10 11 VP), blue squares represent SAM vaccination at varying doses and black circle represents challenge with SARS-CoV-2 virus. N = 5/group. (B) spike S1 IgG endpoint titers, geometric mean (annotated) and geometric SD. LOD = 50, samples below LOD set to ½ LOD. (C) IFNγ ELISpot (SFU/10 6 PBMCs) at specified timepoint post immunization, following overnight stimulation with overlapping peptide pool spanning spike antigen. Mean (annotated) +/-SEM. (D) IL-4 vs IFNγ ELISpot of PBMCs assessed 1-week post boost immunization. Individual animal values (n=5/group). Background corrected values. Diagonal line represents unity line. (E) Pseudovirus neutralization titers (50% inhibition, NT50) assessed in sera at specified timepoint post immunization. LOD = 50, samples < LOD set to ½ LOD. Geometric mean (annotated) and SD. HCS = human convalescent serum assessed by same assay. C = PBS control injected animals assessed 8 weeks post injection. (F) Live virus micro-neutralizing titer (50% inhibition, NT50) at specified timepoint post immunization and post SARS-CoV-2 challenge, geometric mean (annotated) and geometric SD. LOD = 20, samples below LOD set to ½ LOD.

Journal: bioRxiv

Article Title: A self-amplifying mRNA COVID-19 vaccine drives potent and broad immune responses at low doses that protects non-human primates against SARS-CoV-2

doi: 10.1101/2021.11.08.467773

Figure Lengend Snippet: (A) Schematic of SARS-CoV-2 vaccine evaluation and challenge in rhesus macaques. Orange circles represent ChAd immunization (5×10 11 VP), blue squares represent SAM vaccination at varying doses and black circle represents challenge with SARS-CoV-2 virus. N = 5/group. (B) spike S1 IgG endpoint titers, geometric mean (annotated) and geometric SD. LOD = 50, samples below LOD set to ½ LOD. (C) IFNγ ELISpot (SFU/10 6 PBMCs) at specified timepoint post immunization, following overnight stimulation with overlapping peptide pool spanning spike antigen. Mean (annotated) +/-SEM. (D) IL-4 vs IFNγ ELISpot of PBMCs assessed 1-week post boost immunization. Individual animal values (n=5/group). Background corrected values. Diagonal line represents unity line. (E) Pseudovirus neutralization titers (50% inhibition, NT50) assessed in sera at specified timepoint post immunization. LOD = 50, samples < LOD set to ½ LOD. Geometric mean (annotated) and SD. HCS = human convalescent serum assessed by same assay. C = PBS control injected animals assessed 8 weeks post injection. (F) Live virus micro-neutralizing titer (50% inhibition, NT50) at specified timepoint post immunization and post SARS-CoV-2 challenge, geometric mean (annotated) and geometric SD. LOD = 20, samples below LOD set to ½ LOD.

Article Snippet: A standard curve comprised of synthetic RNA containing the target sequence from SARS-CoV-2 isolate WA1 sequence (GenBank Accession Number MN985325.1 ) (Bio-Synthesis, Inc.; Lewisville, TX) was included on each PCR plate for absolute quantitation of SARS-CoV-2 copies in each sample.

Techniques: Enzyme-linked Immunospot, Neutralization, Inhibition, Injection

Subgenomic RNA levels determined by RT-qPCR at specified timepoint post SARS-CoV-2 challenge for each animal in (A) bronchial alveolar lavage (B) oropharyngeal swab or (C) nasal swab. LOD = 422, samples below LOD set to ½ LOD. Geometric mean and SD. Numbers above each bar are numbers of NHP with viral load levels > LOD.

Journal: bioRxiv

Article Title: A self-amplifying mRNA COVID-19 vaccine drives potent and broad immune responses at low doses that protects non-human primates against SARS-CoV-2

doi: 10.1101/2021.11.08.467773

Figure Lengend Snippet: Subgenomic RNA levels determined by RT-qPCR at specified timepoint post SARS-CoV-2 challenge for each animal in (A) bronchial alveolar lavage (B) oropharyngeal swab or (C) nasal swab. LOD = 422, samples below LOD set to ½ LOD. Geometric mean and SD. Numbers above each bar are numbers of NHP with viral load levels > LOD.

Article Snippet: A standard curve comprised of synthetic RNA containing the target sequence from SARS-CoV-2 isolate WA1 sequence (GenBank Accession Number MN985325.1 ) (Bio-Synthesis, Inc.; Lewisville, TX) was included on each PCR plate for absolute quantitation of SARS-CoV-2 copies in each sample.

Techniques: Quantitative RT-PCR

(A) Peak subgenomic RNA levels in bronchial alveolar lavage for each animal determined by RT-qPCR between day 3 and day 10 post SARS-CoV-2 challenge. (B) Peak subgenomic RNA levels in nasal swab for each animal determined by RT-qPCR between day 2 and day 10 post SARS-CoV-2 challenge. LOD = 422, samples below LOD set to ½ LOD. LLOQ = 3,881. Red bar is median. Statistical analyses: Mann-Whitney test for each group compared to unvaccinated control group.

Journal: bioRxiv

Article Title: A self-amplifying mRNA COVID-19 vaccine drives potent and broad immune responses at low doses that protects non-human primates against SARS-CoV-2

doi: 10.1101/2021.11.08.467773

Figure Lengend Snippet: (A) Peak subgenomic RNA levels in bronchial alveolar lavage for each animal determined by RT-qPCR between day 3 and day 10 post SARS-CoV-2 challenge. (B) Peak subgenomic RNA levels in nasal swab for each animal determined by RT-qPCR between day 2 and day 10 post SARS-CoV-2 challenge. LOD = 422, samples below LOD set to ½ LOD. LLOQ = 3,881. Red bar is median. Statistical analyses: Mann-Whitney test for each group compared to unvaccinated control group.

Article Snippet: A standard curve comprised of synthetic RNA containing the target sequence from SARS-CoV-2 isolate WA1 sequence (GenBank Accession Number MN985325.1 ) (Bio-Synthesis, Inc.; Lewisville, TX) was included on each PCR plate for absolute quantitation of SARS-CoV-2 copies in each sample.

Techniques: Quantitative RT-PCR, MANN-WHITNEY

Total genomic RNA levels (N1) determined by RT-qPCR at specified timepoint post SARS-CoV-2 challenge for each animal in (A) bronchial alveolar lavage (B) oropharyngeal swab or (C) nasal swab. LOD = 230, samples below LOD set to ½ LOD. Geometric mean and SD.

Journal: bioRxiv

Article Title: A self-amplifying mRNA COVID-19 vaccine drives potent and broad immune responses at low doses that protects non-human primates against SARS-CoV-2

doi: 10.1101/2021.11.08.467773

Figure Lengend Snippet: Total genomic RNA levels (N1) determined by RT-qPCR at specified timepoint post SARS-CoV-2 challenge for each animal in (A) bronchial alveolar lavage (B) oropharyngeal swab or (C) nasal swab. LOD = 230, samples below LOD set to ½ LOD. Geometric mean and SD.

Article Snippet: A standard curve comprised of synthetic RNA containing the target sequence from SARS-CoV-2 isolate WA1 sequence (GenBank Accession Number MN985325.1 ) (Bio-Synthesis, Inc.; Lewisville, TX) was included on each PCR plate for absolute quantitation of SARS-CoV-2 copies in each sample.

Techniques: Quantitative RT-PCR